Meds for Depression Word Scramble
|
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Question | Answer |
DEPRESSION IS WHAT KIND OF DISORDER | A MOOD/AFFECTIVE |
RELIEF OF SYMPTOMS OF DEPRESSION WITH ANTI-DEPRESSANT THERAPY CAN TAKE HOW LONG | 1-3 WEEKS |
WHEN CAN YOU EXPECT THE FULL BENEFITS OF ANTI-DEPRESSANT THERAPY TO TAKE PLACE | 2-3 MONTHS |
WHAT ARE THE FOUR MAIN GROUPS OF ANTI-DEPRESSANT MEDICATIONS | TCA'S/TRICYCLIC ANTI-DEPRESSANTS SSRI'S/SELECTIVE SEROTONIN REUPTAKE INHIBITORS MOAI'S/MONOAMINE OXIDASE INHIBITORS ATYPICAL ANTIDEPRESSANTS |
WHAT MEDICATIONS ARE UNDER THE CLASSIFICATION OF TCA'S | AMITRIPTYLINE/ELAVIL IMIPRAMINE/TOFRANIL DOXEPIN/SINEQUAN NORTRIPTYLINE/AVENTYL TRIMIPRAMINE/SURMONTIL |
WHAT IS THE EXPECTED PHARMACOLOGICAL ACTION OF TCA'S | BLOCK REUPTAAKE OF NOREPINEPHRINE AND SEROTONIN IN THE SYNAPTIC SPACE THEREBY INTENSIFYING THE EFFECTS OF THESE NEUROTRANSMITTERS |
WHAT ARE THE THERAPEUTIC EFFECTS OF TCA'S | DEPRESSION DEPRESSIVE EPISODES OF BIPOLAR DISORDER CHRONIC PAIN ENURESIS |
WHAT ARE THE SIDE EFFECTS OF USING TCA'S | ORTHOSTATIC HYPOTENSION ANTICHOLINERGIC EFFECTS SEDATION TOXICITY DECREASED SEIZURE THRESHOLD EXCESSIVE SWEATING |
WHAT ARE THE ANTICHOLINERGIC EFFECTS OF TCA'S | DRY MOUTH BLURRED VISION PHOTOPHOBIA URINARY HESITANCY OR RETENTION CONSTIPATION TACHYCARDIA |
WHAT KIND OF TOXICITY RESULTS FROM USING TCA'S | CHOLINERGIC BLOCKADE AND CARDIAC TOXICITY EVIDENCED BY DYSRHYTHMIAS MENTAL CONFUSION AGITATION FOLLOWED BY SEIZURES COMA POSSIBLE DEATH |
TCA'S ARE A PREGNANCY CATEGORY RISK? | C |
TCA'S ARE CONTRAINDICATED IN CLIENTS THAT ? | HAVE SEIZURE DISORDERS |
TCA'S ARE USED CAUTIOUSLY IN CLIENTS WITH | CORONARY ARTERY DISEASE DIABETES LIVER DISORDER KIDNEY DISORDER RESPIRATORY DISORDER URINARY RETENTION AND OBSTRUCTION ANGLE-CLOSURE GLAUCOMA BENIGN PROSTATIC HYPERTROPHY HYPERTHYROIDISM |
INTERACTIONS WITH TCA'S INCLUDE | MAOI'S AND ST JOHNS WORT = SEROTONIN SYNDROME ANTIHISTAMINES = ADDITIVE ANTICHOLINERGIC EFFECTS TCA'S DECREASE EPHEDRINE, AMPHETAMINE EFFECTS ALCOHOL, ANTIHISTAMINES, BENZO'S, OPIOIDS = ADDED CNS DEPRESSANT INCREASED EFFECTS OF EPINEPHRINE, DOPAMINE |
MEDICATIONS CLASSIFIED AS SSRI'S ARE | FLUOXETINE/PROZAC CITALOPRAM/CELEXA ESCITALOPRAM/LEXAPRO PAROXETINE/PAXIL SERTRALINE/ZOLOFT |
WHAT IS THE EXPECTED PHARMACOLOGICAL ACTION OF SSRI'S | SELECTIVELY BLOCK REUPTAKE OF THE MONOAMINE NEUROTRANSMITTER SEROTONIN IN THE SYNAPTIC SPACE THEREBY INTENSIFYING THE EFFECTS OF SEROTONIN |
THERAPEUTIC USES OF SSRI'S ARE | MAJOR DEPRESSION OCD BULIMIA NERVOSA PMDD PANIC DISORDER PTSD |
SIDE EFFECTS OF SSRI'S ARE | SEXUAL DYSFUNCTION CNS STIMULATION WEIGHT LOSS (EARLY IN THERAPY) WEIGHT GAIN (IN LATER THERAPY) SEROTONIN SYNDROME WITHDRAWAL SYMPTOMS HYPONATREMIA RASH SLEEPINESS FAINTNESS LIGHTHEADEDNESS GI BLEEDING BRUXISM |
SEROTONIN SYNDROME MAY BEGIN WHEN | 2-72 HOURS AFTER STARTING THERAPY AND MAY BE LETHAL |
SIDE EFFECTS ASSOCIATED WITH SEROTONIN SYNDROME | MENTAL CONFUSION DIFFICULTY CONCENTRATING FEVER AGITATION ANXIETY HALLUCINATIONS INCOORDINATION HYPERREFLEXIA DIAPHORESIS TREMORS |
WITHDRAWAL SYMPTOMS ASSOCIATED WITH SSRI'S ARE | HEADACHE NAUSEA VISUAL DISTURBANCES ANXIETY DIZZINESS TREMORS |
FLUOXETINE IS A PREGNANCY RISK CATEGORY | C |
FLUOXETINE AND PAROXETINE MAY INCREASE THE RISKS OF WHAT | BIRTH DEFECTS |
SSRI'S ARE CONTRAINDICATED IN CLIENTS TAKING | MAOI'S AND TCA'S |
SSRI'S ARE USED CAUTIOUSLY IN CLIENTS WITH | LIVER DYSFUNCTION RENAL DYSFUNCTION CARDIAC DISEASE SEIZURE DISORDERS DIABETES ULCERS HISTORY OF GI BLEEDING TAKING NSAIDS TAKING ANTI-COAGULANTS |
MAOI'S AND ST JOHNS WORT INCREASE THE RISK OF | SEROTONIN SYNDROME |
FLUOXETINE CAN DISPLACE WARFARIN/COUMADIN FROM BOUND PROTEIN AND RESULT IN WHAT | INCREASED WARFARIN LEVELS |
FLUOXETINE CAN INCREASE THE LEVELS OF TCA'S AND WHAT | LITHIUM |
FLUOXETINE SUPPRESSES PLATELET AGGREGATION AND THUS INCREASES THE RISK OF BLEEDING WHEN USED WITH WHAT | NSAID'S AND ANTI-COAGULANTS |
MEDICATIONS IN THE MAOI CLASS ARE | PHENELZINE/NARDIL ISOCARBOXAZID/MARPLAN TRANYLCYPROMINE/PARNATE SELEGILINE/EMSAM-TRANSDERMAL MAOI |
THE EXPECTED PHARMACOLOGICAL ACTION OF MAOI'S IS | BLOCK THE MAO-A IN THE BRAIN THEREBY INCREASING THE AMOUNT OF NOREPINEPHRINE, DOPAMINE, SEROTONIN AVAILABLE FOR TRANSMISSION OF IMPULSES THIS INTENSIFIES THE RESPONSE AND RELIEVES DEPRESSION |
THERAPEUTIC USES OF MAOI'S ARE | ATYPICAL DEPRESSION BULIMIA NERVOSA OCD |
SIDE EFFECTS OF MAOI'S INCLUDE | CNS STIMULATION ORTHOSTATIC HYPOTENSION HYPERTENSIVE CRISIS LOCAL RASH WITH TRANSDERMAL USE |
WHAT ARE THE SPECIFIC SIDE EFFECTS ASSOCIATED WITH THE CNS STIMULATION | ANXIETY AGITATION MANIA HYPOMANIA |
WHAT CAUSES THE HYPERTENSIVE CRISIS ASSOCIATED WITH USE OF MAOI'S | TYRAMINE CONTAINING FOODS |
WHAT ARE THE SIDE EFFECTS OF HYPERTENSIVE CRISIS ASSOCIATED WITH THE USE OF TYRAMINES AND MAOI'S | HEADACHE NAUSEA INCREASED HEART RATE INCREASED BLOOD PRESSURE |
MAOI'S ARE PREGNANCY RISK CATEGORY | C |
MAOI'S ARE CONTRAINDICATED IN WHAT TYPE OF CLIENTS | TAKING SSRI'S THOSE WITH PHEOCHROMOCYTOMA CARDIOVASCULAR DISEASE CEREBRAL VASCULAR DISEASE SEVERE RENAL INSUFFICENCY |
MAOI'S ARE USED CAUTIOUSLY IN CLIENTS WITH | DIABETES SEIZURE DISORDERS TAKING TCA'S |
TRANSDERMAL SELEGILINE/EMSAM IS CONTRAINDICATED IN CLIENTS TAKING | CARBAMAZEPINE/TEGRETOL OXCARBAZEPINE/TRILEPTAL WHICH MAY INCREASE THE BLOOD LEVELS OF THE MAOI |
INTERACTIONS WITH MAOI'S | INDIRECT ACTING SYMPATHOMIMETIC MEDICATIONS TCA'S SSRI'S MEPERIDINE/DEMEROL TYRAMINE RICH FOODS VASOPRESSORS |
INDIRECT ACTING SYMPATHOMIMETIC MEDICATIONS PROMOTE THE RELEASE OF NOREPINEPHRINE AND CAN LEAD TO WHAT | HYPERTENSIVE CRISIS |
USE OF TCA'S AND MAOI'S CAN LEAD TO WHAT | HYPERTENSIVE CRISIS |
USE OF SSRI'S AND MAOI'S CAN LEAD TO WHAT | SEROTONIN SYNDROME |
ANTIHYPERTENSIVES AND MAOI'S HAVE A ADDITIVE WHAT EFFECT | HYPOTENSIVE |
MEPERIDINE/DEMEROL AND MAOI'SCAN LEAD TO WHAT | HYPERPYREXIA |
CONCURRENT USE OF VASOPRESSORS AND MAOI'S RESULT IN WHAT | HYPERTENSION |
WHAT ARE MEDICATIONS THAT ARE LISTED AS ATYPICAL ANTIDEPRESSANTS | BUPROPRION HCL/WELLBUTRIN |
WHAT IS THE EXPECTED PHARMACOLOGICAL ACTION OF ATYPICAL ANTI-DEPRESSANTS | INHIBITING DOPAMINE UPTAKE |
THERAPEUTIC USES OF ATYPICAL ANTI-DEPRESSANTS ARE | TREATMENT OF DEPRESSION ALTERNATIVE TO SSRI'S FOR CLIENTS UNABLE TO TOLERATE SEXUAL DYSFUNCTION SIDE EFFECTS OF SSRI'S AID TO QUIT SMOKING PREVENTION OF SAD |
SIDE EFFECTS OF ATYPICAL ANTI-DEPRESSANTS | HEADACHE DRY MOUTH GI DISTRESS CONSTIPATION INCREASED HEART RATE NAUSEA RESTLESSNESS INSOMNIA SUPRESSION OF APPETITE WEIGHT LOSS SEIZURES |
BUPROPRION HCL/WELLBUTRIN IS A PREGNANCY RISK CATEGORY WHAT | B |
ATYPICAL ANTI-DEPRESSANTS ARE CONTRAINDICATED IN CLIENTS THAT ARE | TAKING MAOI'S |
ATYPICAL ANTI-DEPRESSANTS ARE USED CAUTIOUSLY IN CLIENTS WHO HAVE | SEIZURE DISORDERS |
ATYPICAL ANTI-DEPRESSANTS INTERACT WITH MAOI'S AND INCREASE THE RISK OF | TOXICITY |
OTHER ATYPICAL ANTIDEPRESSANTS ARE | VENLAFAXINE/EFFEXOR DULOXETINE/CYMBALTA (SNRI'S) MIRTAZAPINE/REMERON REBOXETINE/EDRONAX TRAZADONE/DESYREL |
EFFEXOR AND CYMBALTA'S PHARMACOLOGICAL ACTION IS | INHIBIT SEROTONIN AND NOREPINEPHRINE REUPTAKE THEREBY INCREASING THE AMOUNT OF THESE NEUROTRANSMITTERS AVAILABLE IN BRAIN IMPULSE TRANSMISSION |
MIRTAZAPINE/REMERON'S PHARMACOLOGICAL ACTION | INCREASE RELEASE OF SEROTONIN AND NOREPINEPHRINE AND THEREBY INCREASING THE AMOUNT OF NEUROTRANSMITTERS AVAILABLE FOR IMPULSE TRANSMISSION |
REBOXETINE/EDRONAX'S PHARMACOLOGICAL ACTION | SELECTIVELY INHIBITS THE REUPTAKE OF NOREPINEPHRINE THEREBY INCREASING THE AMOUNT OF NEUROTRANSMITTERS AVAILABLE FOR IMPULSE TRANSMISSION |
TRAZADONE/DESYREL'S PHARMACOLOGICAL ACTION | HAS MODERATE SELECTIVE BLOCKADE OF SEROTONIN RECEPTORS WHICH ALLOWS MORE SEROTONIN TO BE AVAILABLE FOR IMPULSE TRANSMISSION |
Created by:
nursebtanner
Popular Nursing sets